<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04100720</url>
  </required_header>
  <id_info>
    <org_study_id>CP 19-01</org_study_id>
    <nct_id>NCT04100720</nct_id>
  </id_info>
  <brief_title>Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation</brief_title>
  <official_title>Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Biomedical Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovalve Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiovascular Research Foundation, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Biomedical Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and technical performance of the Cardiovalve&#xD;
      Transfemoral System for tricuspid valve replacement. Data collected in the clinical study&#xD;
      will include 30-day safety and performance of the device and delivery system, and long-term&#xD;
      clinical outcomes over a follow-up of 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Cardiovalve Transfemoral System for tricuspid valve replacement&#xD;
&#xD;
      Data collected in the clinical study will include 30-day safety and performance of the device&#xD;
      and delivery system, and long-term clinical outcomes over a follow-up of 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2022</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Primary Performance Endpoint - Technical Success of Cardiovalve Delivery and Function in each participant</measure>
    <time_frame>30 Days</time_frame>
    <description>Cardiovalve Technical Success defined as: I Successful access, delivery and retrieval of the delivery system; II Successful deployment of correct positioning of the first intended implant; III Freedom from emergency surgery or reintervention related to the device or access procedure without any procedural mortality, stroke, and device dysfunction at 30-day follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Performance Endpoint - Clinical Performance - Reduction in Tricuspid Regurgitation severity measured using Echocardiography and compared to baseline</measure>
    <time_frame>30 Days</time_frame>
    <description>Cardiovalve Clinical Performance will be evaluated as: I The reduction in degree of tricuspid regurgitation measured immediately after the procedure compared to baseline; II The reduction in degree of tricuspid regurgitation measured at the time of discharge or 7 days post procedure, whichever comes first, in comparison with baseline&#xD;
Tricuspid Regurgitation is measured using Echocardiography and is graded based on degree of severity using grading conventions from 0 to 4+.&#xD;
0 = absent&#xD;
= mild&#xD;
= moderate&#xD;
= moderate to severe&#xD;
= severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint (Patient Based) Participants Implanted without Major Device Related Adverse Events through thirty days</measure>
    <time_frame>30 Days</time_frame>
    <description>The ability of the Cardiovalve to be implanted without Major Device Related Adverse Events through thirty (30) days including: I Death (Cardiovascular mortality vs non-cardiovascular); II Reintervention (operative or transcatheter) due to progressive or recurrent TR or device related complications; III Disabling stroke; IV Myocardial infarction (MVARC definition); V Major access site and vascular complications; VI Fatal or life-threatening bleeding (MVARC Type III-V); VII Arrhythmia and conduction disorder requiring permanent pacing; VIII Right coronary artery occlusion requiring intervention; IX Cardiac tamponade, X Renal failure requiring dialysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Endpoint - Tricuspid Regurgitation Severity</measure>
    <time_frame>30 days, 3 months, 6 months</time_frame>
    <description>Tricuspid Regurgitation is measured using Echocardiography and is graded based on degree of severity using grading conventions from 0 to 4+.&#xD;
0 = absent&#xD;
= mild&#xD;
= moderate&#xD;
= moderate to severe&#xD;
= severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Endpoint - Cusp Insufficiency</measure>
    <time_frame>30 days, 3 months, 6 months</time_frame>
    <description>Cusp Insufficiency: Change in the degree of the cusp insufficiency as assessed with echocardiography (ordinal) from a higher to a lower value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Endpoint - Unrestricted Movement of Cusps</measure>
    <time_frame>30 days, 3 months, 6 months</time_frame>
    <description>Unrestricted Movement of Cusps: the percentage of medical devices with unrestricted movement of cusps after implantation as assessed with echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Endpoint - New York Heart Association (NYHA) functional class</measure>
    <time_frame>30 days, 3 months, 6 months</time_frame>
    <description>NYHA function class I - IV; Higher functional class represents more severe symptoms of heart failure&#xD;
NYHA Classification - The Stages of Heart Failure:&#xD;
Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.&#xD;
Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.&#xD;
Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest.&#xD;
Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Endpoint - 6 minute walk test</measure>
    <time_frame>30 days, 3 months, 6 months</time_frame>
    <description>6 minute walk test distance (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Endpoint - Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>30 days, 3 months, 6 months</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) - 23 subjective quality of life questions. Assessed before and after implantation. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.&#xD;
There are 3 subscales: Symptom Burden - range 0-100; Physical Limitation - range 0-100; Quality of Life - range 0-100; The total KCCQ score represents the mean (average) of the three subscale scores.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Cardiovalve Transfemoral Tricuspid Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Replacement (Implant) delivered through a transfemoral access</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiovalve Transfemoral Tricuspid Valve</intervention_name>
    <description>The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation</description>
    <arm_group_label>Cardiovalve Transfemoral Tricuspid Valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is 85 ≥ Age ≥ 18 years&#xD;
&#xD;
          2. Participant has severe, symptomatic tricuspid regurgitation (TR) ≥ 3+ based upon&#xD;
             echocardiography, as assessed by Independent core laboratory&#xD;
&#xD;
          3. Participant is New York Heart Association (NYHA) Class II-IVa&#xD;
&#xD;
          4. Participant has left ventricular ejection fraction (LVEF) ≥ 35%&#xD;
&#xD;
          5. Participant distance of 6 minute walk test (6MWT) ≥ 60 m&#xD;
&#xD;
          6. Participant adequately treated based upon medical standards, including for coronary&#xD;
             artery disease, mitral regurgitation and Guideline Directed Medical Therapy (GDMT) for&#xD;
             heart failure for at least 30-days prior to index procedure.&#xD;
&#xD;
          7. Acceptable by the site &quot;Heart Team&quot; including an interventional cardiologist,&#xD;
             cardiothoracic surgeon, heart failure cardiologist and recommended as a candidate for&#xD;
             the Cardiovalve System&#xD;
&#xD;
          8. Participant approved by the Subject Screening Committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known significant intracardiac shunt (e.g. septal defect) or congenital structural&#xD;
             heart disease (PFO's without significant shunts are allowed)&#xD;
&#xD;
          2. Significant coronary artery disease requiring treatment&#xD;
&#xD;
          3. Primary tricuspid disease (e.g. rheumatic, myxomatous degeneration, tricuspid valve&#xD;
             prolapse)&#xD;
&#xD;
          4. Severe right ventricular failure per ASE guidelines1&#xD;
&#xD;
          5. Systolic pulmonary arterial pressure &gt; 65 mmHg as assessed by transthoracic&#xD;
             echocardiography&#xD;
&#xD;
          6. Presence of any known life threatening non-cardiac disease that will limit the&#xD;
             subject's life expectancy to less than one year&#xD;
&#xD;
          7. Cerebrovascular event (stroke, TIA) within the past 3 months&#xD;
&#xD;
          8. Active endocarditis or history of mitral/tricuspid endocarditis within the last 12&#xD;
             months&#xD;
&#xD;
          9. Patient has significant left sided valvular heart disease which requires treatment&#xD;
             (e.g. mitral regurgitation or stenosis, and aortic regurgitation or stenosis)&#xD;
&#xD;
         10. Documented primary coagulopathy or platelet disorder, including thrombocytopenia&#xD;
             (absolute platelet count &lt;90k)&#xD;
&#xD;
         11. Documented evidence of significant renal dysfunction (eGFR&lt;30 ml/min/1.73m2) or on any&#xD;
             form of dialysis at time of screening within the last 4 weeks&#xD;
&#xD;
         12. Contraindication or known allergy to device's components, to anti-coagulation therapy&#xD;
             with vitamin K antagonists or to contrast media that cannot be adequately premedicated&#xD;
&#xD;
         13. Patients unsuitable for implantation because of thrombosis of the lower venous system&#xD;
             or presence of a vena cava filter&#xD;
&#xD;
         14. The patient has contraindication against a transesophageal echo (TEE) during the&#xD;
             procedure&#xD;
&#xD;
         15. Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days)&#xD;
&#xD;
         16. Hepatic insufficiency (MELD &gt; 10)&#xD;
&#xD;
         17. Female patient of child-bearing potential&#xD;
&#xD;
         18. Psychiatric or behavioral disease including known alcohol or drug abuser that is&#xD;
             likely to impair compliance with protocol&#xD;
&#xD;
         19. Requirement for Antibiotic Treatment within the last 48 hours&#xD;
&#xD;
         20. Cardiac Anatomy deemed not suitable for the Cardiovalve Implant&#xD;
&#xD;
         21. Surgical or interventional procedure planned within 30 days prior to index procedure&#xD;
&#xD;
         22. UNOS Status 1 heart transplant or prior orthotropic heart transplantation.&#xD;
&#xD;
         23. Any prior Tricuspid valve surgery or transcatheter Tricuspid valve procedure&#xD;
&#xD;
         24. Modified Rankin Scale &gt; 4 disability&#xD;
&#xD;
         25. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable&#xD;
             cardioverter-defibrillator within one month prior to index procedure&#xD;
&#xD;
         26. Need for any percutaneous cardiovascular intervention, cardiovascular surgery, or&#xD;
             carotid surgery within 30 days of index procedure&#xD;
&#xD;
         27. Currently participating in an investigational drug or another device study which has&#xD;
             not reached its primary endpoint&#xD;
&#xD;
         28. Patient (or legal guardian) unable or unwilling to provide written, informed consent&#xD;
             before study enrollment&#xD;
&#xD;
         29. Chronic oral steroid or other condition that could impair healing response (e.g.&#xD;
             cardiac sarcoidosis or other chronic inflammatory disease).&#xD;
&#xD;
         30. Acutely decompensated heart failure (i.e. hemodynamically unstable or requiring IV&#xD;
             inotrope ) at the time of screening&#xD;
&#xD;
         31. Severe COPD or continuous use of home oxygen&#xD;
&#xD;
         32. Currently participating in another investigational drug or device study that has not&#xD;
             completed the primary endpoint or that clinically interferes with the endpoints of&#xD;
             this study&#xD;
&#xD;
         33. Aortic or pulmonic valve disease requiring surgery&#xD;
&#xD;
         34. Venous peripheral anatomy unsuitable for implant delivery&#xD;
&#xD;
         35. Chronic anemia (Hgb &lt; 9)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lauren Baker, PhD</last_name>
    <phone>(508) 351-8632</phone>
    <email>lbaker@boston-biomedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Pierce, MS</last_name>
    <phone>(508) 351-8632</phone>
    <email>kpierce@boston-biomedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University / Bluhm Cardiovascular Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center / NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Tamim Nazif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

